Russian researchers say a new cancer vaccine is ready for clinical use following years of testing. The Federal Medical and Biological Agency (FMBA) revealed the breakthrough during the Eastern Economic Forum in Vladivostok.

Enteromix: An mRNA-based approach

The vaccine, named Enteromix, is built on mRNA technology, the same method used in several Covid-19 vaccines. Instead of introducing a weakened virus, the mRNA instructs the body’s cells to produce proteins that prompt the immune system to target and attack cancer cells.

Promising trial results

According to FMBA head Veronika Skvortsova, the vaccine has undergone extensive preclinical trials over the past three years. Tests showed the treatment was safe even after repeated doses and proved effective in slowing tumor growth. In some cases, tumors shrank or their growth slowed by 60–80%, depending on the cancer type. Researchers also reported improved survival rates among trial subjects.

Focus on colorectal and other cancers

The first application of Enteromix will target colorectal cancer, which affects the large intestine. Researchers are also developing versions of the vaccine for glioblastoma, an aggressive brain cancer, and several forms of melanoma, including ocular melanoma that impacts the eye.

A step forward in cancer treatment

The announcement marks a significant milestone for Russian oncology research. While global experts caution that more clinical testing in humans will be needed before widespread use, the FMBA says the vaccine is now ready to move beyond laboratory trials.

Image Source: Google | Image Credit: Respective Owner